Incidence, Risk Factors, and Management of Infusion-Related Reactions in Breast Cancer Patients Receiving Trastuzumab

Background.Trastuzumab has become a mainstay of therapy for humanepidermalgrowthfactorreceptor-2overexpressed breast cancer in nearly all stages of the disease. Like many monoclonal antibodies, trastuzumab is associated with infusionrelatedreactions(IRRs)thatarenotwelldescribed,andincidence varies widely between reports (0.7%–40% of patients). MaterialsandMethods. Aretrospectivechartreviewofbreast cancer patients who received trastuzumab was conducted. The primary objective was to describe the incidence, risk factors, and management of IRRs during the first 12 weeks of trastuzumab therapy in a general population of breast cancer